Carlsmed has launched a state-of-the-art digital production line that will enable the firm to deliver its aprevo personalized spinal fusion implants to hospitals in less than 10 days.

“This advancement is more than just a technical achievement,” Carlsmed Chairman/CEO Mike Cordonnier said. “The reduced lead time makes aprevo available for surgeries with shorter scheduling windows, increasing addressable procedures and furthering our commitment to making personalized surgery accessible to every patient who needs it.”

Carlsmed’s current portfolio of patient-specific devices is designed specifically for lumbar spine fusion surgery. The company is developing patient-specific implants for cervical spine fusion surgery and received U.S. Food and Drug Administration Breakthrough Device designation for cervical fusions last year. Carlsmed is planning to launch aprevo for cervical fusions by the end of 2025.

“The aprevo implants were crucial for my recovery,” said Renee Schreiner, a patient who received the aprevo procedure. “When my surgeon told me that personalized spine surgery was available to me, I immediately felt more comfortable choosing to have surgery. Knowing that my implant was designed just for me made all the difference.”

Clinical publications show significant improvements in patient outcomes for aprevo personalized procedures compared to traditional spine fusion surgery.

Carlsbad, Calif.-based Carlsmed is a commercial stage medical technology company developing personalized spine surgery solutions. aprevo reportedly is the only commercially available custom made anatomically designed interbody for spine fusion surgery.